Bank of America Corp DE Acquires 1,487 Shares of Medpace Holdings, Inc. $MEDP

Bank of America Corp DE raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 212,183 shares of the company’s stock after acquiring an additional 1,487 shares during the period. Bank of America Corp DE’s holdings in Medpace were worth $101,888,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. AQR Capital Management LLC lifted its position in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the last quarter. Franklin Resources Inc. grew its position in Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after acquiring an additional 183,645 shares in the last quarter. Norges Bank purchased a new position in Medpace in the fourth quarter worth $102,156,000. Finally, Goldman Sachs Group Inc. increased its stake in Medpace by 92.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after acquiring an additional 166,654 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.0%

Shares of NASDAQ MEDP opened at $590.67 on Friday. The firm’s fifty day moving average is $522.14 and its 200 day moving average is $492.78. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The company has a market cap of $16.49 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 2.61 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the company posted $3.10 EPS. The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 3,510 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total value of $2,106,035.10. Following the transaction, the chief executive officer directly owned 638,946 shares in the company, valued at $383,373,989.46. This trade represents a 0.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,087 shares of company stock valued at $16,203,054 over the last ninety days. 20.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Two equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.